Compounds > 3,4-dihydroxyphenylacetic acid

3,4-dihydroxyphenylacetic acid and allyl sulfide

3,4-dihydroxyphenylacetic acid has been researched along with allyl sulfide in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bergquist, F; Engberg, G; Jonason, J; Nissbrandt, H1
Bartoli, C; Corsini, GU; Dinucci, D; Pardini, C; Vaglini, F; Viaggi, C1

Other Studies

2 other study(ies) available for 3,4-dihydroxyphenylacetic acid and allyl sulfide

ArticleYear
Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: a new metabolic pathway?
    Synapse (New York, N.Y.), 2001, Jun-15, Volume: 40, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Allyl Compounds; Animals; Antioxidants; Chelating Agents; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP2E1 Inhibitors; Ditiocarb; Dopamine; Energy Metabolism; Enzyme Inhibitors; Extracellular Space; Homovanillic Acid; Isothiocyanates; Male; Microdialysis; Neostriatum; Neurons; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sulfides

2001
Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Journal of neurochemistry, 2004, Volume: 91, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allyl Compounds; Animals; Blotting, Western; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP2E1 Inhibitors; Disease Models, Animal; Ditiocarb; Dopamine; Drug Synergism; Enzyme Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Neostriatum; Parkinsonian Disorders; Reverse Transcriptase Polymerase Chain Reaction; Substantia Nigra; Sulfides; Tyrosine 3-Monooxygenase

2004